Close Menu

drug development

In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.

AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.

The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.